Elana Sydney

Elana Sydney

Auto-generated profile, based on publicly available information

Elana Sydney

Department of Medicine, NYC Health + Hospitals/Jacobi, Albert Einstein College of Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRoopa Kalyanaraman Marcello
Roopa Kalyanaraman Marcello
JDJohanna Dolle
Johanna Dolle
SGShelia Grami
Shelia Grami
RARichard Adule
Richard Adule
ZLZeyu Li
Zeyu Li
JJJessica Jacobson
Jessica Jacobson
Background: New York City (NYC) bore the greatest burden of COVID-19 in the United States early in the pandemic. In this case series, we describe characteristics and outcomes of racially and ethnically diverse patients tested for and hospitalized with COVID-19 in New York City’s public hospital system. Methods: We reviewed the electronic health records of all patients who received a SARS-CoV-2 test between March 5 and April 9, 2020, with follow up through April 16, 2020. The primary outcomes were a positive test, hospitalization, and death. Demographics and comorbidities were also assessed. Results: 22254 patients were tested for SARS-CoV-2. 13442 (61%) were positive; among those, the median age was 52.7 years (interquartile range [IQR] 39.5–64.5), 7481 (56%) were male, 3518 (26%) were Black, and 4593 (34%) were Hispanic. Nearly half (4669, 46%) had at least one chronic disease (27% diabetes, 30% hypertension, and 21% cardiovascular disease). Of those testing positive, 6248 (46%) were hospitalized. The median age was 61.6 years (IQR 49.7–72.9); 3851 (62%) were male, 1950 (31%) were Black, and 2102 (34%) were Hispanic. More than half (3269, 53%) had at least one chronic disease (33% diabetes, 37% hypertension, 24% cardiovascular disease, 11% chronic kidney disease). 1724 (28%) hospitalized patients died. The median age was 71.0 years (IQR 60.0, 80.9); 1087 (63%) were male, 506 (29%) were Black, and 528 (31%) were Hispanic. Chronic diseases were common (35% diabetes, 37% hypertension, 28% cardiovascular disease, 15% chronic kidney disease). Male sex, older age, diabetes, cardiac history, and chronic kidney disease were significantly associated with testing positive, hospitalization, and death. Racial/ethnic disparities were observed across all outcomes. Conclusions and relevance: This is the largest and most racially/ethnically diverse case series of patients tested and hospitalized for COVID-19 in New York City to date. Our findings highlight disparities in outcomes that can inform prevention and testing recommendations.

26 August 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
ESElana R. Sydney
Elana R. Sydney
PKPreeti Kishore
Preeti Kishore
ILIsaac Laniado
Isaac Laniado
LRLisa M. Rucker
Lisa M. Rucker
KBKomal Bajaj
Komal Bajaj
MZMichael J. Zinaman
Michael J. Zinaman

6 March 2025 in The Journal of the American Dental Association
Verified
Journal Article
Closed access
NLNadia Laniado
Nadia Laniado
PSParth Shah
Parth Shah
MCMegan Cloidt
Megan Cloidt
ERErica Robles
Erica Robles
VBVictor Badner
Victor Badner
ESElana Sydney
Elana Sydney

29 March 2022 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Closed access
PBPrasanth Balasubramanian
Prasanth Balasubramanian
CBCesar Gabriel Berto
Cesar Gabriel Berto
EHElaine Rph Hassan
Elaine Rph Hassan
NVNancy Valentine
Nancy Valentine
GVGabriele De Vos
Gabriele De Vos
ESElana Sydney
Elana Sydney
Background: Coronavirus disease 2019 (Covid-19) presents as a mild infection in up to 84% of cases out of which 10% progress to more severe disease requiring hospitalization and 33% to 69% progress to long haulers. The real-world data on the use of anti–severe acute respiratory syndrome coronavirus 2 spike neutralizing monoclonal antibodies, namely casirivimab and imdevimab, as well as bamlanivimab for mild Covid-19 is limited. Methods: We conducted a retrospective cohort study on patients who received casirivimab and imdevimab or bamlanivimab for the treatment of mild Covid-19. Results: Three hundred forty patients were included in the study with the mean age of the cohort 54.7 ± 17.5 years, and 36.5% of them were men. Thirty-day outcomes revealed that 300 (88.2%) patients were followed up to 30 days, out of which 243 patients (71.5%) were asymptomatic at 30 days, 57 patients (16.7%) had symptoms at 30 days out of which 9 patients (2.6%) had an ED visit or were admitted because of the worsening of Covid-19 in 30 days and 3 patients (0.9%) died. Conclusions: Our study suggests that early infusion with monoclonal antibodies may decrease the development of long haulers. Further studies with randomized-controlled trials are needed to understand more about monoclonal antibodies in the prevention of long-term sequelae especially in the setting of ongoing viral mutations.

28 May 2020 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Closed access
ESElana Sydney
Elana Sydney
MZMichael J. Zinaman
Michael J. Zinaman
PKPreeti Kishore
Preeti Kishore
AEAngela Esannason
Angela Esannason
DFDana M. Ferrante
Dana M. Ferrante
KBKomal Bajaj
Komal Bajaj